

1044
03C0



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Stuyver *et al.*

Serial No.: 10/023,637 Group Art Unit: Not Yet Assigned

Filed: December 17, 2001 Examiner: Not Yet Assigned

For: Antiviral Agents for Treatment of Flaviviridae Infections

Assistant Commissioner for Patents
Washington, DC 20231

June 5, 2002

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying Form PTO-1449A. Copies of all listed references are enclosed as well as the PCT Search Report. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,

Josephine Young
Registration No. 48,308

KING & SPALDING
191 Peachtree Street
Atlanta, GA 30303
404-572-4600 (Telephone)
404-572-5145 (Facsimile)



CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

A handwritten signature in black ink, appearing to read "Josephine Young".

Date: June 5, 2002

**COPY OF PAPERS
ORIGINALLY FILED**

PTO/SB/08A (08-00)

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p align="center">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p align="center">(use as many sheets as necessary)</p> <p align="center">JUN 14 2002</p> <p align="center">PATENT & TRADEMARK OFFICE</p>				<i>Complete if Known</i>	
				Application Number	10/023,637
				Filing Date	December 17, 2001
				First Named Inventor	Stuyver et al.
				Group Art Unit	
				Examiner Name	N/A
				Attorney Docket Number	PHAR1030US
Sheet	of	1			

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	AA	5658890		Pankiewicz, K. W. et al.	8/19/97
	AB	4748173		Nelson P. et al.	5/31/88

FOREIGN PATENT DOCUMENTS							
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number	Kind Code ² (if known)			
	AC	WO	94/29331		Sloan Kettering	12/22/94	
	AD	WO	98/34942		Inspire Pharma	8/13/98	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ⁶
		Office ³	Number	Kind Code ² (if known)	Date	
	AE	LESIAK, K ET AL., <i>J. of Med. Chem.</i> , vol. 40, 1997, 2533-2538.				
	AF	RILEY, TA, <i>J. of Heterocyclic Chem.</i> , vol 24., 1 July 1987, 955-964.				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.